ArticleEuropean journal of neurology2025
Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropathies associated with IgA monoclonal gammopathy are poorly understood, and the interpretation of the presence of such gammopathy in a patient with neuropathy may be challenging.
methodsThe neurological and hematological features of all patients newly diagnosed with IgA gammopathy by immunofixation in our center from January 2016 to December 2020 were retrospectively analyzed. Patients with neuropathy were identified through the medical records. The etiology was reviewed by two neurologists and classified into three groups: (i) IgA-related neuropathies, (ii) IgA-unrelated neuropathies with an identified alternative etiology, and (iii) neuropathies of uncertain relationship with IgA (NURIA) based on a negative extensive work-up.
resultsAmong 585 patients with IgA gammopathy, 79 had neuropathy (14%). Neuropathy was IgA-related in 10 patients (13%): eight AL amyloidosis and two POEMS. In this group, the core features were neuropathic pain, autonomic dysfunction, fatigue or weight loss, and a lambda light chain. IgA-unrelated neuropathies were more frequent (N = 64, 81%), encompassing mainly chemotherapy-induced (N = 34) and diabetic (N = 15) neuropathies. Five patients (6%) were classified as NURIA: four had mild sensory-predominant length-dependent axonal neuropathy, and one had severe, progressive, motor-predominant axonal neuropathy.
conclusionsIn patients with IgA gammopathy, neuropathies have a low prevalence and a wide etiological spectrum. AL amyloidosis and POEMS syndrome are rare but crucial to identify, as disease-modifying treatments are available. Future studies should help better characterize the rare cases of neuropathy with an uncertain relationship to IgA gammopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.